Clinical trial registry record

Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients

A registered EARLY_PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Not Yet Recruiting.
Evidence
Registered early phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 27, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07728981
Last registry update
July 27, 2026
Status
Not Yet Recruiting
Phase
EARLY Phase 1
Sponsor
Tianjin Medical University Eye Hospital
Enrollment
49
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered EARLY_PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
EARLY Phase 1
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
49
Population
ALL · 50 Years to 85 Years
Duration
2026-07-25 to 2027-12-31
Intervention
Aflibercept 8mg
Comparator
Not reported
Outcomes measured
VEGF-A levels in the patient's aqueous humor — From enrollment to the end of treatment at 0 months、2months、5months、8mon…; Proportion of patients who did not receive remedial treatment — From enrollment to the end of treatment at 12 months; best corrected visual acuity (BCVA) — From enrollment to the end of treatment at 12 months; central retinal thickness (CMT) — From enrollment to the end of treatment at 12 months; VEGF-B levels in the patient's aqueous humor — From enrollment to the end of treatment at 0 months、2months、5months、8mon…; placental growth factor (PIGF) levels in the patient's aqueous humor — From enrollment to the end of treatment at 0 mon…; Ang-2 levels in the patient's aqueous humor — From enrollment to the end of treatment at 0 months、2months、5months、8mont…; IL-6 levels in the patient's aqueous humor — From enrollment to the end of treatment at 0 months、2months、5months、8month…; IL-8 levels in the patient's aqueous humor — From enrollment to the end of treatment at 0 months、2months、5months、8month…; Average number of doses in the 12th month — "From enrollment to the end of treatment at 12 months; the average area/volume of macular neovascularization (MNV) — From enrollment to the end of treatment at 0 month、2month…; intraretinal fluid (IRF) or subretinal fluid (SRF) in the foveal area — From enrollment to the end of treatment at 2mon…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · EARLY Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON